Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Dengue Vaccine Formulations in Healthy Adults
NCT00740155Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2008
- Primary completion
- Oct 2009
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever, sponsored by Sanofi. Started Aug 2008; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT00740155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00740155.